LTS appoints Bas van Buijtenen as new Chief Executive Officer
LTS Lohmann Therapie-Systeme AG is very pleased to announce the appointment of Mr. Bas van Buijtenen to the role of Chief Executive Officer effective 1 June 2020.
Completion of solar panel installation at LTS Corp.
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is pleased to announce the completion of the installation of solar panels atop of its warehouse building of its US affiliate, LTS Lohmann Therapy Systems, Corp.
LTS announces the appointment of David Doles as new President and Chief Executive Officer for its US affiliate LTS Corp.
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020.
Transdermal Therapeutic Systems – Still an attractive Technology
This web seminar shows the characteristics and advantages of TTS [...]
European patent granted for LTS’ asenapine TTS
An European Patent for LTS’ application relating to an asenapine transdermal therapeutic system (TTS).
German health authorities grant LTS the manufacturer’s authorisation for capsules
Inspection successfully concluded. In September, the German health authorities extended the manufacturer’s authorisation for LTS Lohmann Therapie-Systeme AG (LTS) to include capsules.
LTS donates fire-truck to Zichow fire brigade!
The LTS plant fire brigade donates a decommissioned fire-fighting vehicle to the Zichow fire brigade, whose fire-truck has burnt down during a fire in the engine house in February of this year.
LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment
LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis.
Dr. Reddy’s re-launches generic of Buprenorphine and Naloxone Sublingual Film
LTS congratulates its business partner Dr. Reddy’s Laboratories Ltd. for the US launch of its Buprenorphine and Naloxone Sublingual Film.
EsoCap announces kick-off of an industrial development collaboration with LTS
EsoCap AG and LTS Lohmann Therapy-Systeme AG announced the start of cooperation on industrial development of a unique drug delivery technology for diseases of the upper gastrointestinal tract.